Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and ...
REDMOND, Wash., Sept. 24, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren (izalontamab brengitecan) and ...
Source: Image provided by Dr. Laura Gabayan Do you often feel overwhelmed by society’s focus on productivity and accomplishments? As a physician and researcher, I was convinced that building my resume ...
Antibody-drug conjugates (ADCs) represent a cutting-edge approach in cancer therapy. The three essential components of an ADC include: the mAb, the linker, and the cytotoxic payload. The mAb in ...
- Investor conference call and webcast to discuss data and clinical trial plans on June 2, 2025, at 7:00 a.m. CT / 8:00 a.m. ET / 8:00 p.m. HKT SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab ...
After a full-dress review of the subjunctive in the preceding chapters, this form of the English language should no longer hold any terrors for us. With a clearer understanding of its uses and ...
VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results